Novel Treatment For Pusher Syndrome Using Physical Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Recent (within 2 months) unilateral stroke
- Burke Lateropulsion Scale ≥ 2
- Age 21 to 89 years
- Ability to provide informed consent
- English-speaking
Exclusion Criteria:
- Prior stroke within the past 6 months
- Cerebellar stroke
- Stroke-related brain imaging (MRI or CT) unavailable
- Global or receptive aphasia
- Prior documented neurologic disorder (e.g., multiple sclerosis, Parkinson's)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Control
Standard Physical Therapy
|
|
|
Experimental: Intervention
Novel Physical Therapy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recovery from pusher syndrome as measured by changes in the Burke Lateropulsion Scale score over time.
Time Frame: Initial, and then weekly until discharge from inpatient rehabilitation unit. Average inpatient stay is expected to be no greater than 4 weeks.
|
The Burke Lateropulsion Scale (BLS) is used in the literature to measure the presence of pusher syndrome.
We will measure BLS upon admission and at weekly intervals to monitor whether patients in the experimental group demonstrate faster recovery than the control group, as demonstrated by change in BLS score over change in time (days).
|
Initial, and then weekly until discharge from inpatient rehabilitation unit. Average inpatient stay is expected to be no greater than 4 weeks.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 5150231
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.